Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:diagnosis
|
| gptkbp:developedBy |
gptkb:Natera
|
| gptkbp:launched |
2017
|
| gptkbp:regulates |
laboratory developed test (LDT)
|
| gptkbp:technology |
personalized, tumor-informed assay
|
| gptkbp:type |
blood
|
| gptkbp:usedFor |
minimal residual disease detection
recurrence monitoring cancer monitoring treatment response assessment circulating tumor DNA detection early detection of relapse |
| gptkbp:usedIn |
clinical trials
|
| gptkbp:website |
https://www.natera.com/oncology/signatera/
|
| gptkbp:bfsParent |
gptkb:Natera
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
Signatera
|